Income statement
GBP
Annual
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -26K | -26K | -18K |
| Operating Income | -6M | -5M | -5M | -3M |
| EBITDA | -6M | -5M | -5M | -3M |
| Net Income | -6M | -4M | -5M | -2M |
| EPS (Diluted) | — | — | — | — |
Healthcare
Live Price
Offline$0.0919
+0.00% today
1Y Change
+118.81%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 252 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Poolbeg Pharma PLC (POLBF) is a Healthcare stock with a market cap of $30.00M and listed on OTC. The stock last traded around $0.09 and up 118.8% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -46.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -46.8%, free cash flow -18.7% with operating margin 0.0% and ROIC -53.6%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines POLBF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
POLBF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
POLBF Max Drawdown
-20.36%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for POLBF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$2.3M
+50.1% YoY
Free Cash Flow
-$2.2M
+55.1% YoY
Revenue Growth
+0.0%
EPS Growth
-46.8%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
GBP
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -26K | -26K | -18K |
| Operating Income | -6M | -5M | -5M | -3M |
| EBITDA | -6M | -5M | -5M | -3M |
| Net Income | -6M | -4M | -5M | -2M |
| EPS (Diluted) | — | — | — | — |
Balance sheet
GBP
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Cash & Equivalents | 8M | 12M | 16M | 21M |
| Total Assets | 10M | 15M | 19M | 23M |
| Total Liabilities | 974K | 986K | 966K | 438K |
| Shareholder Equity | 9M | 14M | 18M | 23M |
| Total Debt | 0 | 0 | 0 | 0 |
| Net Debt | -8M | -12M | -16M | -21M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
+50.9% YoY
Capital Expenditures
81K
+86.4% YoY
Free Cash Flow
2M
+55.1% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-53.9%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.